Brief: Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin
04/01/2017 14:00
Jan 4 (Reuters) - Cytrx Corp CYTR.O :
* Cytrx granted type b pre-nda meeting with U.S. FDA for
registration pathway with aldoxorubicin as a treatment for
patients with relapsed soft tissue sarcomas
* Cytrx Corp- cytrx expects overall survival data to be
available in 2017
Source text for Eikon: ID:nPn767cbta
Further company coverage: CYTR.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C